MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.020
+0.120
+3.08%
Closed 16:00 05/11 EDT
OPEN
4.140
PREV CLOSE
3.900
HIGH
4.250
LOW
3.890
VOLUME
30.64K
TURNOVER
--
52 WEEK HIGH
8.18
52 WEEK LOW
3.200
MARKET CAP
28.53M
P/E (TTM)
-2.2771
1D
5D
1M
3M
1Y
5Y
Eyegate Pharmaceuticals Files Shelf for Up to About 3.9 Million Common Shares on Behalf of Selling Stockholders
MT Newswires · 04/19 03:16
BRIEF-Eyegate Pharmaceuticals Files Prospectus Related To Offering Of 3.9 Million Shares Of Common Stock Of Co By Selling Stockholders - SEC Filing
reuters.com · 04/16 21:00
Eyegate (EYEG) Gets a Buy Rating from H.C. Wainwright
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Eyegate (EYEG) today and set a price target of $14.00. The company's shares closed last
SmarterAnalyst · 04/05 10:15
EyeGate Pharma Appoints Kenneth Gayron And Aron Shapiro To Its Board Of Directors
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has
Benzinga · 04/01 11:15
10-K: EYEGATE PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. Forward-Looking Statements The...
Edgar Online - (EDG = 10Q, 10K) · 03/25 23:06
Eyegate Pharmaceuticals misses on revenue
Eyegate Pharmaceuticals (EYEG): FY Revenue of $0.01M (-99.6% Y/Y) misses by $0.02M.Cash and cash equivalents were $1.186 million as of December 31, 2020, compared to $3.777 million as of December
Seekingalpha · 03/25 20:43
Press Release: EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update
Dow Jones · 03/25 20:15
Analysts Offer Insights on Healthcare Companies: Eyegate (EYEG), Tiziana Life Sciences (TLSA) and Mustang Bio (MBIO)
SmarterAnalyst · 02/03 11:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYEG. Analyze the recent business situations of EyeGate Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EYEG stock price target is 12.13 with a high estimate of 14.00 and a low estimate of 10.25.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 1.92M
% Owned: 27.02%
Shares Outstanding: 7.10M
TypeInstitutionsShares
Increased
2
15.19K
New
3
1.45K
Decreased
2
23.34K
Sold Out
1
1.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.55%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Executive Director
Stephen From
Chief Executive Officer
Franz Obermayr
Chief Financial Officer
Sarah Romano
Vice President
Michael Manzo
Lead Director/Independent Director
Paul Chaney
Director
Steven Boyd
Director
I. Keith Maher
Other
Mike Garanzini
Director
Keith Maher
Independent Director
Kenneth Gayron
Independent Director
Aron Shapiro
Independent Director
Praveen Tyle
No Data
  • All
  • Financials
  • Insiders
More
About EYEG
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Webull offers kinds of Eyegate Pharmaceuticals Inc stock information, including NASDAQ:EYEG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYEG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYEG stock methods without spending real money on the virtual paper trading platform.